| Identification | Back Directory | [Name]
Reltecimod | [CAS]
1447799-33-8 | [Synonyms]
P2TA
P-2TA
Reltecimod
Reltecimod (peptide)
D-Alanine, D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl- | [Molecular Formula]
C46H72N10O15S | [MDL Number]
MFCD33022133 | [MOL File]
1447799-33-8.mol | [Molecular Weight]
1037.2 |
| Chemical Properties | Back Directory | [Boiling point ]
1473.8±65.0 °C(Predicted) | [density ]
1.315±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
3.26±0.10(Predicted) | [color ]
White to off-white | [Sequence]
H-d-Ala-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-d-Ala-OH |
| Hazard Information | Back Directory | [Uses]
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2]. | [in vivo]
Reltecimod (1.25-5 mg/kg; i.v.) increases the survival rate of mice infected with different bacteria[2]. | Animal Model: | Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)[2] | | Dosage: | 1.25 or 5 mg/kg | | Administration: | i.v.; single dosage; at 4 h post infection | | Result: | Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.
Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6. |
| Animal Model: | Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)[2] | | Dosage: | 2.5 or 5 mg/kg | | Administration: | i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection | | Result: | Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.
Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.
Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6. |
| Animal Model: | Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2] | | Dosage: | 1.25, 2.5, or 5 mg/kg | | Administration: | i.v.; single dosage | | Result: | Increased day 7 survival by up to 100%. |
| [References]
[1] Shirvan, A., et al. Reltecimod. T-cell-specific surface glycoprotein CD28 (TP44) antagonist, CD28 homodimer interface mimetic peptide, Treatment of necrotizing soft-tissue infection. Drugs Fut 2018, 43(4): 243
[2] Edgar, R., Tarrio, M.L., Maislin, G.?et al.?Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection.?Int J Pept Res Ther?26, 1669–1683 (2020). |
|
| Company Name: |
Combio (Suzhou) Ltd.
|
| Telephone: |
17751201929; 17751201929 |
| Website: |
http://www.combiosz.com/ |
|